U.S. Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews
This article was originally published in The Rose Sheet
Executive Summary
The Public Access to SunScreens Coalition will recommend a user-fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.
You may also be interested in...
FDA’s OTC Monograph Division Head Recognizes Need To Speed Process
Addressing industry stakeholders as a member of a CHPA conference panel, FDA’s OTC monograph division chief Scott Furness says the agency shares companies’ frustration with the sluggish pace of monograph finalization. However, he shares some good news on time and extent applications.
Lawsuit Seeking FDA Triclosan Action Stays Alive On Appeal
A court ruling allowing an advocacy group to move forward in its suit against FDA could pave the way for future litigation intended to force the agency to complete delayed regulations.
FDA Questions Spray Sunscreen Safety, Efficacy & Monograph Status
FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.